GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cynata Therapeutics Ltd (STU:51S) » Definitions » Balance Sheet Cash And Cash Equivalents

Cynata Therapeutics (STU:51S) Balance Sheet Cash And Cash Equivalents


View and export this data going back to 2023. Start your Free Trial

What is Cynata Therapeutics Balance Sheet Cash And Cash Equivalents?

Please go to this page to see Cash And Cash Equivalents for non-financial companies.


Cynata Therapeutics Business Description

Industry
Traded in Other Exchanges
Address
100 Cubitt Street, Level 3, Cremorne, VIC, AUS, 3121
Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus. There are currently three active clinical trials taking place using Cymerus technology which are attempting to treat osteoarthritis, respiratory distress, and diabetic foot ulcers.